Medicash has renewed its partnership with skin cancer screening app SkinVision.
Medicash initially introduced the SkinVision app in June 2020 as an added benefit to its corporate policyholders, subsequently extending it to all policyholders.
Medicash policyholders can access the SkinVision app at no additional cost and the firm revealed that to date policyholders have checked over 80,000 skin spots and moles with the SkinVision app.
With 30.9% of all ‘high risk’ checks leading to clinical referrals, free access to SkinVision has meant that 308 Medicash customers have been recommended to access crucial early treatment for a variety of skin cancers, the provider added.
The SkinVision app uses advanced technology, including artificial intelligence and machine learning algorithms, to analyse images of the skin for signs of potential skin cancer.
Andy Roberts, finance and IT director at Medicash, said: “We are delighted to renew our partnership with SkinVision, reinforcing our commitment to supporting the health and wellbeing of our policyholders.
“The SkinVision app empowers individuals to become more proactive in monitoring their skin health, leading to early detection and better treatment outcomes.
“We are proud to offer this valuable resource to all our policyholders across the UK.”
Roosmarijn Rodenburg, head of marketing and growth at SkinVision, added: “It’s good to see that during our three-year partnership more than 80,000 skin checks have been performed in which several hundred possible skin cancers have been recognised that needed a medical follow-up.
“We look forward to working with Medicash going forward to drive awareness of skin cancer among its policyholders and detecting cancers early when they have the best chance for successful treatment.”
